<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://archopht.ama-assn.org">
<title>Archives of Ophthalmology current issue</title>
<link>http://archopht.ama-assn.org</link>
<description>Archives of Ophthalmology informs readers of progress, problems, and pertinent research in the practice of ophthalmology through the monthly publication of peer-reviewed original contributions and observations. Archives is one of the best-read, most-frequently cited publications in its field. Special departments provide in-depth information on new instruments, surgical techniques, socioeconomics, epidemiology and biostatistics.</description>
<prism:coverDisplayDate>Nov  1 2009 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>Archives of Ophthalmology</prism:publicationName>
<prism:issn>0003-9950</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1408?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1412?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1423?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1428?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1436?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1442?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1449?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1461?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1468?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1475?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1483?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1493?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1494?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1499?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1500?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1505?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1510?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1511?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1519?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1520?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1522?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1528?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1530?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1532?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1534?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1538?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1540?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1544?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1547?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1548?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1550?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1551?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1552?rss=1" />
  <rdf:li rdf:resource="http://archopht.ama-assn.org/cgi/content/short/127/11/1553?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://archopht.ama-assn.org/icons/misc/titlereprint.gif" />
</channel>

<image rdf:about="http://archopht.ama-assn.org/icons/misc/titlereprint.gif">
<title>Archives of Ophthalmology</title>
<url>http://archopht.ama-assn.org/icons/misc/titlereprint.gif</url>
<link>http://archopht.ama-assn.org</link>
</image>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1408?rss=1">
<title><![CDATA[About This Journal [About This Journal]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1408?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:title><![CDATA[About This Journal [About This Journal]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1408</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1408</prism:startingPage>
<prism:section>About This Journal</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1412?rss=1">
<title><![CDATA[Progression of Age-Related Macular Degeneration After Cataract Surgery [Clinical Sciences]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1412?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To document age-related macular degeneration (AMD) progression after cataract surgery.</p>
<p><b>Methods&nbsp;</b> Surgeons prospectively enrolled patients with nonneovascular AMD who were awaiting cataract surgery. Fluorescein angiography was performed preoperatively and at the postoperative week 1, month 3, and month 12 visits. Incidence of neovascular AMD development within 12 months after operation was the primary outcome measure.</p>
<p><b>Results&nbsp;</b> A total of 108 subjects were enrolled. Of 86 eyes with preoperatively photographically confirmed nonneovascular AMD, 71 had gradable images by month 12. Neovascular AMD was observed in 9 of 71 eyes (12.7%; 95% confidence interval, 6.0%-22.7%). The progression rate between week 1 and month 12 decreased to 3 of 65 eyes (4.6%; 95% confidence interval, 1.0%-12.9%) after excluding 5 neovascular events identified on the postoperative week 1 visit and 1 case with missing photographs at this visit.</p>
<p><b>Conclusion&nbsp;</b> The low incidence rate of neovascular AMD development between 1 week and 1 year after cataract surgery did not support the hypothesis that cataract surgery increases the risk of AMD progression. Several eyes appeared to have disease progression on postsurgery week 1 fluorescein angiograms, suggesting that many cases of presumed progression to neovascular AMD following cataract surgery may have been present prior to cataract surgery, but not recognized owing to lens opacity.</p>
]]></description>
<dc:creator><![CDATA[Dong, L. M., Stark, W. J., Jefferys, J. L., Al-Hazzaa, S., Bressler, S. B., Solomon, S. D., Bressler, N. M.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Aging/ Geriatrics, Ophthalmology, Ophthalmological Disorders, Cataracts/ Lens, Macular Degeneration, Ophthalmological Procedures, Ophthalmological Procedures, Other]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.152</dc:identifier>
<dc:title><![CDATA[Progression of Age-Related Macular Degeneration After Cataract Surgery [Clinical Sciences]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1419</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1412</prism:startingPage>
<prism:section>Clinical Sciences</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1423?rss=1">
<title><![CDATA[Corneal Endothelial Cell Loss 9 Years After Excimer Laser Keratorefractive Surgery [Clinical Sciences]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1423?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To determine the long-term changes in the corneal endothelium after laser in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK).</p>
<p><b>Methods&nbsp;</b> Twenty-nine eyes (16 patients) received myopic LASIK or PRK, with intended correction to emmetropia. Central endothelial photographs were taken before and 9 years after surgery and were analyzed by the same masked investigator after appropriate calibration for magnification. Comparisons were made by using generalized estimating equation models to account for any correlation between fellow eyes of the same patient. The annual exponential rate of cell loss was compared with cell loss during a 10-year period in 42 normal (unoperated) corneas of 42 subjects.</p>
<p><b>Results&nbsp;</b> Endothelial cell density 9 years after LASIK and PRK had decreased by 5.3% from preoperative density (<I>P</I>&nbsp;&lt;&nbsp;.001), whereas coefficient of variation of cell area (<I>P</I>&nbsp;=&nbsp;.24) and percentage of hexagonal cells (<I>P</I>&nbsp;=&nbsp;.19) did not change. The mean annual rate of cell loss after refractive surgery (0.6% [standard deviation, 0.8%]) was not different from that in normal corneas (0.6% [0.5%], <I>P</I>&nbsp;=&nbsp;.88; minimum detectable difference&nbsp;=&nbsp;0.5%; &nbsp;=&nbsp;.05; &beta;&nbsp;=&nbsp;.20).</p>
<p><b>Conclusions&nbsp;</b> Laser in situ keratomileusis and PRK had no long-term effect on the corneal endothelium. Corneas that have undergone LASIK or PRK can be considered for use as donors for posterior lamellar keratoplasty procedures.</p>
]]></description>
<dc:creator><![CDATA[Patel, S. V., Bourne, W. M.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Corneal Disorders, Ophthalmological Procedures, Laser Surgery, Refractive Surgery, Quality of Care, Patient Safety/ Medical Error]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.192</dc:identifier>
<dc:title><![CDATA[Corneal Endothelial Cell Loss 9 Years After Excimer Laser Keratorefractive Surgery [Clinical Sciences]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1427</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1423</prism:startingPage>
<prism:section>Clinical Sciences</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1428?rss=1">
<title><![CDATA[Long-term Outcomes of Keratolimbal Allograft for Total Limbal Stem Cell Deficiency Using Combined Immunosuppressive Agents and Correction of Ocular Surface Deficits [Clinical Sciences]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1428?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To determine the long-term outcomes of keratolimbal allograft (KLAL).</p>
<p><b>Methods&nbsp;</b> Scores of such risks as infrequent blinking, blink-related microtrauma, conjunctival inflammation, elevated intraocular pressure, dry eye, symblepharon, lagophthalmos, and previous KLAL or penetrating keratoplasty (PKP) failure were calculated and recorded before, during, and after KLAL. Prolonged oral mycophenolate mofetil and tacrolimus and short-term prednisone and acyclovir were administered in 12 eyes (10 consecutive patients) with total limbal stem cell deficiency after KLAL. Ten eyes underwent subsequent PKP.</p>
<p><b>Results&nbsp;</b> More corrective measures were required in eyes with higher risk scores. During a follow-up of 61.2 months (standard deviation [SD], 18.2; range, 36-91 months) after KLAL, postoperative epithelial breakdown due to exposure occurred late in the period after PKP and remained a primary risk. Mean daily doses of 1.4 g of mycophenolate mofetil and 1.6 mg of tacrolimus were administered for 52.7 months (SD, 22.5; range, 23-91 months) with few adverse effects and reached trough levels of 1.6 &micro;g/mL (SD, 0.6 &micro;g/mL) and 4.5 ng/mL (SD, 2 ng/mL), respectively. Keratolimbal allograft and PKP rejection was noted in 2 and 3 eyes, respectively, though there was a reversal in 1 eye in each group, yielding final KLAL and PKP survivals in 10 and 8 eyes, respectively, and ambulatory visual acuity of up to 20/20 in 10 eyes for 67.2% of the entire follow-up period.</p>
<p><b>Conclusion&nbsp;</b> Correction of ocular surface deficits combined with an immunosuppressive regimen further improves the long-term outcome of KLAL in eyes with total limbal stem cell deficiency.</p>
]]></description>
<dc:creator><![CDATA[Liang, L., Sheha, H., Tseng, S. C. G.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Corneal Disorders, Ophthalmological Procedures, Ophthalmological Procedures, Other, Transplantation, Transplantation, Other, Drug Therapy, Drug Therapy, Other, Immunology, Immunology, Other]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.263</dc:identifier>
<dc:title><![CDATA[Long-term Outcomes of Keratolimbal Allograft for Total Limbal Stem Cell Deficiency Using Combined Immunosuppressive Agents and Correction of Ocular Surface Deficits [Clinical Sciences]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1434</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1428</prism:startingPage>
<prism:section>Clinical Sciences</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1436?rss=1">
<title><![CDATA[Outcomes of Ahmed Glaucoma Valve Implantation in Children With Primary Congenital Glaucoma [Clinical Sciences]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1436?rss=1</link>
<description><![CDATA[
<p><b>Objectives&nbsp;</b> To evaluate the long-term efficacy of intraocular pressure reduction and complications of Ahmed glaucoma valve (AGV) implantation in children with primary congenital glaucoma.</p>
<p><b>Methods&nbsp;</b> The medical records of patients with primary congenital glaucoma who underwent AGV implantation with a minimum follow-up of 6 months were reviewed. The primary outcome measure was cumulative probability of success, defined as intraocular pressure greater than 5 mm Hg and less than 23 mm Hg and at least a 15% reduction from the preoperative intraocular pressure, without serious complications, additional glaucoma surgery, or loss of light perception.</p>
<p><b>Results&nbsp;</b> Thirty eyes of 19 children with primary congenital glaucoma who underwent AGV implantation with a minimum follow-up of 6 months were reviewed. The children had a mean (SD) age of 1.8 (2.6) years, a mean (SD) preoperative intraocular pressure of 28.4 (6.7) mm Hg, and a mean (SD) follow-up time of 57.6 (48.0) months. The cumulative probability of success was 63% in 1 year and 33% in 5 years. After a second AGV implantation, the cumulative probability of success was 86% in 1 and 2 years and 69% in 5 years. Hispanic ethnicity (<I>P</I>&nbsp;=&nbsp;.02) and being female (<I>P</I>&nbsp;=&nbsp;.005) were associated with increased risk of failure.</p>
<p><b>Conclusions&nbsp;</b> Thirty-three percent of AGV implantations in children with primary congenital glaucoma were successful after 5 years of follow-up. With the implantation of a second AGV, the 5-year success rate increased to 69%.</p>
]]></description>
<dc:creator><![CDATA[Ou, Y., Yu, F., Law, S. K., Coleman, A. L., Caprioli, J.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Glaucoma, Pediatric Ophthalmology, Pediatrics, Congenital Malformations, Pediatrics, Other, Prognosis/ Outcomes]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.267</dc:identifier>
<dc:title><![CDATA[Outcomes of Ahmed Glaucoma Valve Implantation in Children With Primary Congenital Glaucoma [Clinical Sciences]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1441</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1436</prism:startingPage>
<prism:section>Clinical Sciences</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1442?rss=1">
<title><![CDATA[Diffuse Glaucomatous Structural and Functional Damage in the Hemifield Without Significant Pattern Loss [Clinical Sciences]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1442?rss=1</link>
<description><![CDATA[
<p><b>Objectives&nbsp;</b> To compare the retinal nerve fiber layer (RNFL) thickness and retinal sensitivity in the normal visual hemifield of glaucomatous eyes with localized visual field loss with those of normal eyes and eyes with suspected glaucoma, and to evaluate the relationship between RNFL atrophy and glaucoma severity.</p>
<p><b>Methods&nbsp;</b> One randomly selected eye of each subject underwent standard automated perimetry, stereoscopic photography, scanning laser polarimetry with enhanced corneal compensation, and time-domain and spectral-domain optical coherence tomography (OCT). Mean retinal sensitivity values were calculated in the normal standard automated perimetry hemifield of the glaucoma group and randomly selected hemifields in the normal and suspected glaucoma groups. The mean RNFL thickness values corresponding to the normal hemifield were calculated. Glaucoma severity was judged using standard automated perimetry pattern standard deviation and the Heidelberg retina tomograph&ndash;derived linear cup-disc ratio.</p>
<p><b>Results&nbsp;</b> Fifty subjects were enrolled in each group. Mean RNFL thickness in the normal hemifield obtained using spectral-domain OCT, time-domain OCT, and scanning laser polarimetry with enhanced corneal compensation was significantly (<I>P</I>&nbsp;&le;&nbsp;.01) thinner in the glaucoma group compared with the normal and suspected glaucoma groups. Mean retinal sensitivity in the normal hemifield was significantly (<I>P</I>&nbsp;&lt;&nbsp;.001) reduced in the glaucoma group compared with the normal and suspected glaucoma groups. The Heidelberg retina tomograph&ndash;derived cup-disc ratio was significantly correlated with mean RNFL thickness in the normal hemifield obtained using spectral-domain OCT, time-domain OCT, and scanning laser polarimetry with enhanced corneal compensation (<I>P</I>&nbsp;&le;&nbsp;.01).</p>
<p><b>Conclusions&nbsp;</b> Diffuse RNFL atrophy and retinal sensitivity loss exist in glaucomatous eyes with localized standard automated perimetry deficits. Glaucomatous damage affects both structure and function in a linear proportion.</p>
]]></description>
<dc:creator><![CDATA[Grewal, D. S., Sehi, M., Greenfield, D. S.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Glaucoma, Retinal/ Chorioretinal Disorders]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.196</dc:identifier>
<dc:title><![CDATA[Diffuse Glaucomatous Structural and Functional Damage in the Hemifield Without Significant Pattern Loss [Clinical Sciences]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1448</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1442</prism:startingPage>
<prism:section>Clinical Sciences</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1449?rss=1">
<title><![CDATA[A New Macular Dystrophy With Anomalous Vascular Development, Pigment Spots, Cystic Spaces, and Neovascularization [Clinical Sciences]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1449?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To clinically phenotype an inherited macular dystrophy with peculiar intraretinal pigment spots, cysts, and hemorrhage in a 24-year-old female proband and her family.</p>
<p><b>Methods&nbsp;</b> Extended family members of the proband underwent dilated fundus examination, optical coherence tomography, and, in selected cases, fluorescein angiography and electroretinography.</p>
<p><b>Results&nbsp;</b> Seventeen family members, representing 3 generations and ranging in age from 5 to 64 years, were clinically examined. Visual acuities ranged from 20/20 to 20/200. Amblyopia and strabismus were frequently present in affected individuals. Consistent with an autosomal dominant pattern of inheritance, 7 family members had multiple central macular cystic spaces and flat, round, densely pigmented spots within the retina. There were right-angle vessels and telangiectasis in the central macula. Two subjects showed evidence of active macular neovascularization with leakage on fluorescein angiography at ages 7 and 24 years, which was responsive to either focal laser or a single injection of bevacizumab. In those cases examined, multifocal electroretinography showed a diminished foveal response.</p>
<p><b>Conclusions&nbsp;</b> This spotted cystic neovascular macular dystrophy appears to represent a new autosomal dominant retinal condition. Because these patients are at risk for choroidal neovascularization, identification of the responsible gene may provide insight into the mechanisms of pathological neovascularization.</p>
]]></description>
<dc:creator><![CDATA[Mahajan, V. B., Russell, S. R., Stone, E. M.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Choroidal Neovascularization, Corneal Disorders, Macular Disorders, Retinal/ Chorioretinal Disorders, Genetics, Genetic Disorders]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.210</dc:identifier>
<dc:title><![CDATA[A New Macular Dystrophy With Anomalous Vascular Development, Pigment Spots, Cystic Spaces, and Neovascularization [Clinical Sciences]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1457</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1449</prism:startingPage>
<prism:section>Clinical Sciences</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1461?rss=1">
<title><![CDATA[The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study System for Evaluation of Optical Coherence Tomograms: SCORE Study Report 4 [Clinical Sciences]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1461?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To describe grading procedures for optical coherence tomographic (OCT) images of participants in the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study.</p>
<p><b>Methods&nbsp;</b> Optical coherence tomograms were taken at clinical sites with the Stratus OCT using fast macular and crosshair scan protocols. Paper prints of images were evaluated at a central reading center. Quality evaluation identified the accuracy of OCT-measured retinal thickness data and was categorized as good, fair, borderline, or ungradable. Manual measurement of center point thickness was performed on borderline images. Morphological evaluation identified cystoid spaces, subretinal fluid, and vitreoretinal interface abnormalities. Reproducibility of grading was assessed through formal quality control exercises.</p>
<p><b>Results&nbsp;</b> A randomly selected set of 106 images was identified for quality control. The first 2 annual regrades showed 91% and 89% intergrader agreement for OCT quality. Intraclass correlation for manually measured center point thickness was 0.99 per year. For morphological variables, intergrader agreement for cystoid spaces was 83% and 76%. Reproducibility for subretinal fluid and vitreoretinal interface abnormalities could not be interpreted owing to their limited presence in the sample.</p>
<p><b>Conclusion&nbsp;</b> Optical coherence tomogram evaluation procedures used in the SCORE Study are reproducible and can be used for multicenter longitudinal studies of retinal vein occlusion.</p>
]]></description>
<dc:creator><![CDATA[Domalpally, A., Blodi, B. A., Scott, I. U., Ip, M. S., Oden, N. L., Lauer, A. K., VanVeldhuisen, P. C., for the SCORE Study Investigator Group]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Macular Disorders, Retinal/ Chorioretinal Disorders, Ophthalmological Procedures, Ocular Imaging, Drug Therapy, Drug Therapy, Other]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.277</dc:identifier>
<dc:title><![CDATA[The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study System for Evaluation of Optical Coherence Tomograms: SCORE Study Report 4 [Clinical Sciences]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1467</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1461</prism:startingPage>
<prism:section>Clinical Sciences</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1468?rss=1">
<title><![CDATA[Dry Eye Reversal and Corneal Sensation Restoration With Topical Naltrexone in Diabetes Mellitus [Laboratory Sciences]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1468?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To determine if topical application of naltrexone hydrochloride (NTX), an opioid antagonist, restores tear production and corneal sensation in rats with diabetes mellitus.</p>
<p><b>Methods&nbsp;</b> Type 1 diabetes was induced with streptozotocin in rats. Tear production was measured by the Schirmer test, and corneal sensitivity, by an esthesiometer. Eye drops of 10<sup>&ndash;5</sup>M NTX or sterile vehicle were administered either once only or 4 times a day for 1 or 5 days; a single drop of insulin (1 U) was given once only.</p>
<p><b>Results&nbsp;</b> Dry eye and corneal insensitivity were detected in the diabetic rats beginning 5 weeks after streptozotocin injection. One drop of NTX or 4 times a day for 1 or 5 days reestablished tear production and corneal sensitivity within 1 hour of administration. The reversal of dry eye lasted for up to 2 to 3 days depending on drug regimen, but restitution of corneal sensation lasted for 4 to 7 days. Topical application of 1 eye drop of insulin restored corneal sensitivity within 1 hour and lasted for at least 2 days. In contrast, 1 eye drop of insulin did not increase tear production at 1, 24, or 48 hours compared with diabetic animals receiving sterile vehicle.</p>
<p><b>Conclusion&nbsp;</b> Topical treatment with NTX normalizes tear production and corneal sensitivity in type 1 diabetic rats.</p>
<p><b>Clinical Relevance&nbsp;</b> Topical application of NTX to the ocular surface may serve as an important strategy for treating dry eye and corneal anesthesia in diabetes. Its effect, if any, in other forms of decreased corneal sensitivity and/or dry eye should be investigated.</p>
]]></description>
<dc:creator><![CDATA[Zagon, I. S., Klocek, M. S., Sassani, J. W., McLaughlin, P. J.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Corneal Disorders, Dry Eye Syndromes, Drug Therapy, Drug Therapy, Other, Endocrine Diseases, Diabetes Mellitus]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.270</dc:identifier>
<dc:title><![CDATA[Dry Eye Reversal and Corneal Sensation Restoration With Topical Naltrexone in Diabetes Mellitus [Laboratory Sciences]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1473</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1468</prism:startingPage>
<prism:section>Laboratory Sciences</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1475?rss=1">
<title><![CDATA[Minocycline Inhibition of Photoreceptor Degeneration [Laboratory Sciences]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1475?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To determine whether systemic minocycline can protect photoreceptors in experimental retinal detachment (RD).</p>
<p><b>Methods&nbsp;</b> Retinal detachment was induced in mice by subretinal injection of sodium hyaluronate, 1.4%. In 1 experiment, mice received daily injections of minocycline (group 1) or saline (group 2). In a second experiment, mice were treated with minocycline or saline beginning 24 hours prior, immediately after, or 24 hours after experimental RD. In both experiments, photoreceptor cell survival and apoptosis were assessed by immunohistochemistry with primary antibodies against photoreceptor cell markers, rod rhodopsin, and cone opsin, and by terminal deoxynucleotidyl transferase-mediated dUTP-biotin end labeling.</p>
<p><b>Results&nbsp;</b> Photoreceptor cell apoptosis was detected at day 1 after experimental RD, with apoptotic cells peaking in number at day 3 and dropping by day 7. Treatment with minocycline significantly reduced the number of apoptotic photoreceptor cells associated with RD when given 24 hours before or even 24 hours after RD.</p>
<p><b>Conclusions&nbsp;</b> Our data suggest that minocycline may be useful in the treatment of photoreceptor degeneration associated with RD, even when given up to 24 hours after RD.</p>
<p><b>Clinical Relevance&nbsp;</b> Use of minocycline in patients with macula-off RD may prevent photoreceptor apoptosis and glial cell proliferation, improving final visual outcomes.</p>
]]></description>
<dc:creator><![CDATA[Yang, L., Kim, J.-H., Kovacs, K. D., Arroyo, J. G., Chen, D. F.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Retinal Detachment, Ophthalmological Procedures, Vitreoretinal Surgery, Drug Therapy, Drug Therapy, Other]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.288</dc:identifier>
<dc:title><![CDATA[Minocycline Inhibition of Photoreceptor Degeneration [Laboratory Sciences]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1480</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1475</prism:startingPage>
<prism:section>Laboratory Sciences</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1483?rss=1">
<title><![CDATA[Association Between Dietary Fat Intake and Age-Related Macular Degeneration in the Carotenoids in Age-Related Eye Disease Study (CAREDS): An Ancillary Study of the Women's Health Initiative [Epidemiology]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1483?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To evaluate the relationships between the amount and type of dietary fat and intermediate age-related macular degeneration (AMD).</p>
<p><b>Design&nbsp;</b> Women aged 50 to 79 years with high and low lutein intake from 3 sites of the Women's Health Initiative Observational Study were recruited into the Carotenoids in Age-Related Eye Disease Study. Fat intake from 1994 through 1998 was estimated using food frequency questionnaires, and AMD was assessed photographically from 2001 through 2004.</p>
<p><b>Results&nbsp;</b> Intakes of -6 and -3 polyunsaturated fatty acids, which were highly correlated (<I>r</I>&nbsp;=&nbsp;0.8), were associated with approximately 2-fold higher prevalence of intermediate AMD in high vs low quintiles. However, monounsaturated fatty acid intake was associated with lower prevalence. Age interactions were often observed. In women younger than 75 years (n&nbsp;=&nbsp;1325), total fat and saturated fatty acid intakes were associated with increased prevalence of AMD (multivariate adjusted odds ratios [95% confidence interval] for intermediate AMD, 1.7 [1.0-2.7] for quintile 5 vs quintile 1 for total fat [<I>P</I>&nbsp;=&nbsp;.10 for trend] and 1.6 [0.7-3.6] for saturated fatty acids [<I>P</I>&nbsp;=&nbsp;.23 for trend]). The associations were reversed in older women.</p>
<p><b>Conclusions&nbsp;</b> These results support a growing body of evidence suggesting that diets high in several types of fat may contribute to the risk of intermediate AMD and that diets high in monounsaturated fatty acids may be protective.</p>
]]></description>
<dc:creator><![CDATA[Parekh, N., Voland, R. P., Moeller, S. M., Blodi, B. A., Ritenbaugh, C., Chappell, R. J., Wallace, R. B., Mares, J. A., for the CAREDS Research Study Group]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Aging/ Geriatrics, Ophthalmology, Ophthalmological Disorders, Macular Degeneration, Public Health, Diet]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.130</dc:identifier>
<dc:title><![CDATA[Association Between Dietary Fat Intake and Age-Related Macular Degeneration in the Carotenoids in Age-Related Eye Disease Study (CAREDS): An Ancillary Study of the Women's Health Initiative [Epidemiology]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1493</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1483</prism:startingPage>
<prism:section>Epidemiology</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1493?rss=1">
<title><![CDATA[Rapid Optic Nerve Infiltration by Diffuse Large B-Cell Lymphoma [Ophthalmic Images]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1493?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Dorrepaal, S. J., Margolin, E.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Ocular/ Adnexal Tumors, Ophthalmological Procedures, Ocular Imaging, Diagnosis, Hematology/ Hematologic Malignancies, Leukemias/ Lymphomas]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.287</dc:identifier>
<dc:title><![CDATA[Rapid Optic Nerve Infiltration by Diffuse Large B-Cell Lymphoma [Ophthalmic Images]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1493</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1493</prism:startingPage>
<prism:section>Ophthalmic Images</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1494?rss=1">
<title><![CDATA[Prediction of Proliferative Diabetic Retinopathy With Hemoglobin Level [Epidemiology]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1494?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To investigate the role of hemoglobin (HGB) level in predicting proliferative diabetic retinopathy (PDR).</p>
<p><b>Methods&nbsp;</b> We assessed 426 individuals without PDR at baseline (213 men; 213 women) from the Pittsburgh Epidemiology of Diabetes Complications Study, an 18-year prospective cohort study of childhood-onset type 1 diabetes. Presence of PDR was determined by stereo fundus photography. Cox proportional hazards modeling with stepwise regression was used to determine the independent association of HGB level with PDR. Analyses were sex specific.</p>
<p><b>Results&nbsp;</b> There were 206 events. Although the incidence of PDR did not vary by sex (48% in both men and women), in men, HGB exhibited a positive linear relationship with 18-year incidence of PDR (hazard ratio,&nbsp;1.33; 95% confidence interval, 1.10-1.60; <I>P</I>&nbsp;=&nbsp;.003), while in women, HGB level exhibited a quadratic relationship with PDR (<I>P</I>&nbsp;&lt;&nbsp;.001). After multivariable adjustment for univariately significant covariates, HGB level remained significantly predictive of PDR in both men (<I>P</I>&nbsp;=&nbsp;.004) and women (<I>P</I>&nbsp;=&nbsp;.04).</p>
<p><b>Conclusion&nbsp;</b> Higher HGB level predicts the incidence of PDR in type 1 diabetes mellitus, though the association varies by sex, being linear and positive in men and quadratic in women.</p>
]]></description>
<dc:creator><![CDATA[Conway, B. N., Miller, R. G., Klein, R., Orchard, T. J.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Diabetic Retinopathy, Macular Disorders, Endocrine Diseases, Diabetes Mellitus]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.274</dc:identifier>
<dc:title><![CDATA[Prediction of Proliferative Diabetic Retinopathy With Hemoglobin Level [Epidemiology]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1499</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1494</prism:startingPage>
<prism:section>Epidemiology</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1499?rss=1">
<title><![CDATA[June 2009 Archives Web Quiz Winner [Archives Web Quiz Winner]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1499?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Oncology, Skin Cancer, Ophthalmology, Ophthalmological Disorders, Ocular/ Adnexal Tumors, Dermatology, Dermatologic Disorders, Pediatrics, Congenital Malformations, Neonatology and Infant Care, Melanoma]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.238</dc:identifier>
<dc:title><![CDATA[June 2009 Archives Web Quiz Winner [Archives Web Quiz Winner]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1499</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1499</prism:startingPage>
<prism:section>Archives Web Quiz Winner</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1500?rss=1">
<title><![CDATA[Risk of Cataract Extraction Among Adult Retinoblastoma Survivors [Epidemiology]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1500?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To investigate the risk of cataract extraction among adult retinoblastoma survivors.</p>
<p><b>Design&nbsp;</b> A retrospective cohort study was performed on retinoblastoma survivors who received the diagnosis from 1914 to 1984 and were interviewed in 2000. Lens doses were estimated from radiotherapy records. The cumulative time interval to cataract extraction between dose groups was compared using the log-rank test and Cox regression.</p>
<p><b>Results&nbsp;</b> Seven hundred fifty-three subjects (828 eyes) were available for analysis for an average of 32 years of follow-up. During this period, 51 cataract extractions were reported. One extraction was reported in an eye with no radiotherapy compared with 36 extractions in 306 eyes with 1 course of radiotherapy and 14 among 38 eyes with 2 or 3 treatments. The average time interval to cataract extraction in irradiated eyes was 51 years (95% confidence interval [CI], 48-54) following 1 treatment and 32 years (95% CI, 27-37) after 2 or 3 treatments. Eyes exposed to a therapeutic radiation dose of 5 Gy or more had a 6-fold increased risk (95% CI, 1.3-27.2) of cataract extraction compared with eyes exposed to 2.5 Gy or less.</p>
<p><b>Conclusions&nbsp;</b> The results emphasize the importance of ophthalmologic examination of retinoblastoma survivors who have undergone radiotherapy. The risk of cataract extraction in untreated eyes with retinoblastoma is comparable with the risk of the general population.</p>
]]></description>
<dc:creator><![CDATA[Chodick, G., Kleinerman, R. A., Stovall, M., Abramson, D. H., Seddon, J. M., Smith, S. A., Tucker, M. A.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Oncology, Oncology, Other, Ophthalmology, Ophthalmological Disorders, Cataracts/ Lens, Ocular/ Adnexal Tumors, Retinal/ Chorioretinal Disorders, Retinal Detachment, Ophthalmological Procedures, Vitreoretinal Surgery, Ophthalmological Procedures, Other, Radiation Therapy]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.271</dc:identifier>
<dc:title><![CDATA[Risk of Cataract Extraction Among Adult Retinoblastoma Survivors [Epidemiology]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1504</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1500</prism:startingPage>
<prism:section>Epidemiology</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1505?rss=1">
<title><![CDATA[Effect of Trichiasis Surgery on Visual Acuity Outcomes in Ethiopia [Epidemiology]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1505?rss=1</link>
<description><![CDATA[
<p><b>Objectives&nbsp;</b> To determine the effect of trichiasis surgery on visual acuity.</p>
<p><b>Methods&nbsp;</b> A total of 439 participants in the Surgery for Trichiasis, Antibiotics to Prevent Recurrence (STAR) trial had visual and subjective concerns measured before and 6 months after surgery. Trichiasis surgery was performed in at least 1 eye by integrated eye care workers. Visual acuity was measured using illiterate E versions of Early Treatment Diabetic Retinopathy Study charts with standardized, forced-choice procedures. Improvement was defined as improvement in visual acuity greater than 1 line (5 letters).</p>
<p><b>Results&nbsp;</b> The mean improvement in visual acuity for the eyes that had surgery was 0.129 logMAR units (<I>P</I>&nbsp;&lt;&nbsp;.001). Surgery was associated with improvement in visual acuity compared with no surgery (odds ratio, 1.68; 95% confidence interval, 1.04-2.70). Independent predictors of visual acuity improvement in the eyes that had surgery included the number of lashes touching the globe prior to surgery and baseline visual acuity. Among patients, 93.8% described significant pain and 90.4% significant photophobia at baseline compared with only 1.4% and 0.9%, respectively, following surgery.</p>
<p><b>Conclusions&nbsp;</b> Surgery to correct trichiasis appears to provide significant visual acuity improvement as well as a decrease in subjective concerns in patients with trachomatous trichiasis.</p>
<p><b>Trial Registration&nbsp;</b> clinicaltrials.gov Identifier: <inter-ref locator-type="url" locator="http://clinicaltrials.gov/show/NCT00347776">NCT00347776</inter-ref></p>
]]></description>
<dc:creator><![CDATA[Woreta, T. A., Munoz, B. E., Gower, E. W., Alemayehu, W., West, S. K.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Corneal Disorders, External Eye Disease, Ophthalmological Disorders, Other, Ophthalmological Procedures, Ophthalmological Procedures, Other, Prognosis/ Outcomes]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.278</dc:identifier>
<dc:title><![CDATA[Effect of Trichiasis Surgery on Visual Acuity Outcomes in Ethiopia [Epidemiology]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1510</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1505</prism:startingPage>
<prism:section>Epidemiology</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1510?rss=1">
<title><![CDATA[Allvar Gullstrand [Ophthalmological Numismatics]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1510?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmology, Other, Humanities]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.293</dc:identifier>
<dc:title><![CDATA[Allvar Gullstrand [Ophthalmological Numismatics]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1510</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1510</prism:startingPage>
<prism:section>Ophthalmological Numismatics</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1511?rss=1">
<title><![CDATA[Mutational Hot Spot Potential of a Novel Base Pair Mutation of the CSPG2 Gene in a Family With Wagner Syndrome [Ophthalmic Molecular Genetics]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1511?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To report a 3-generation white family clinically diagnosed variably with Wagner, Stickler, and Jansen syndromes and screened for sequence variants in the <I>COL2A1</I> and <I>CSPG2</I> genes. Wagner syndrome is an autosomal dominant vitreoretinopathy with a predisposition to retinal detachment and cataracts. It has significant phenotypic overlap with allelic Jansen syndrome and ocular Stickler syndrome type 1. Sticker syndrome type 1 maps to chromosome 12q13.11-q13.2, with associated <I>COL2A1</I> gene mutations. Wagner syndrome maps to chromosome 5q13-q14 and is associated with mutations in <I>CSPG2</I> encoding versican, a proteoglycan present in human vitreous.</p>
<p><b>Methods&nbsp;</b> Genomic DNA samples derived from venous blood were collected from all family members. Complete sequencing of <I>COL2A1</I> was performed on a proband. Primers for polymerase chain reaction and sequencing were designed to cover all exon and intron-exon boundaries. Direct sequencing of <I>CSPG2</I> was performed on all family member samples.</p>
<p><b>Results&nbsp;</b> No detectable <I>COL2A1</I> mutations were noted, making the diagnosis of ocular Stickler syndrome highly unlikely for this family. A unique base pair substitution (c.9265&nbsp;+&nbsp;1G>T) in intron 8 of the <I>CSPG2</I> gene cosegregating with disease status was identified. This mutation occurred in a highly conserved previously reported splice site with a similar base pair substitution (G>A). Direct sequencing of this splice site mutation in 107 unrelated external controls revealed no variants, supporting the rarity of this base pair change and its causation in Wagner syndrome. This novel base pair substitution is thought to cause the deletion of exon 8 and formation of a truncated protein product.</p>
<p><b>Conclusion&nbsp;</b> Mutation screening of <I>CSPG2</I> in autosomal dominant vitreoretinopathy families is important for accurate diagnosis.</p>
<p><b>Clinical Relevance&nbsp;</b> This study underscores the importance of obtaining extensive pedigree information and comparative ophthalmologic clinical information, as the phenotypic findings may vary greatly among independent family members. The study also affirms the paradigm shift from diagnosis assignment based on eponyms to that based on gene mutation type.</p>
]]></description>
<dc:creator><![CDATA[Ronan, S. M., Tran-Viet, K.-N., Burner, E. L., Metlapally, R., Toth, C. A., Young, T. L.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Cataracts/ Lens, Retinal/ Chorioretinal Disorders, Retinal Detachment, Diagnosis, Genetics, Genetic Counseling/ Testing/ Therapy]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.273</dc:identifier>
<dc:title><![CDATA[Mutational Hot Spot Potential of a Novel Base Pair Mutation of the CSPG2 Gene in a Family With Wagner Syndrome [Ophthalmic Molecular Genetics]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1519</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1511</prism:startingPage>
<prism:section>Ophthalmic Molecular Genetics</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1519?rss=1">
<title><![CDATA[Dr Thompson's Eye Water [Ophthalmological Ephemera]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1519?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmology, Other, Humanities]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.283</dc:identifier>
<dc:title><![CDATA[Dr Thompson's Eye Water [Ophthalmological Ephemera]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1519</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1519</prism:startingPage>
<prism:section>Ophthalmological Ephemera</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1520?rss=1">
<title><![CDATA[Acellular Dermal Graft as a Treatment of Recurrent Conjunctival Wound Dehiscence [Surgical Technique]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1520?rss=1</link>
<description><![CDATA[
<p>Acellular dermal graft (ADG) functions as a scaffold to harness nature's regenerative healing process. Frequently used in eyelid and orbital surgery, application of ADG to the globe has not been reported, to our knowledge. In a patient with a complicated ocular history, wound dehiscence with Ahmed valve extrusion developed. Several attempts to repair the extrusion were made with commonly used biomaterials, resulting in recurrent wound dehiscence. An ADG was placed with glue and then sutured to the edge of the dehiscence. The conjunctiva grew over the graft, allowing the wound to close. The wound site has been intact for more than 3 years. We report the first successful use to date of ADG on the globe. In difficult cases of wound repair on the globe, ADG may be an alternative to conventional graft materials.</p>
]]></description>
<dc:creator><![CDATA[Du, T. T., Saffra, N.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, External Eye Disease, Ophthalmological Procedures, Ophthalmological Procedures, Other, Dermatology, Dermatologic Disorders, Transplantation, Transplantation, Other, Wound Healing, Facial Plastic Surgery, Biomaterials and Implants]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.158</dc:identifier>
<dc:title><![CDATA[Acellular Dermal Graft as a Treatment of Recurrent Conjunctival Wound Dehiscence [Surgical Technique]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1521</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1520</prism:startingPage>
<prism:section>Surgical Technique</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1522?rss=1">
<title><![CDATA[Analysis of Ophthalmology Workforce and Delivery of Emergency Department Eye Care in Florida [Socioeconomics and Health Services]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1522?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To measure annual population-based volume of emergency department (ED) eye care and concurrent ophthalmology on-call coverage.</p>
<p><b>Methods&nbsp;</b> Analysis and correlation of the 2006 Florida Agency of Health Care Administration ED and inpatient data sets with the 2007 Florida Physician Workforce Survey.</p>
<p><b>Results&nbsp;</b> The Florida Physician Workforce Survey showed 46.3% of ophthalmologists surveyed took ED call in Florida in 2006. Based on estimates derived from the survey, 462 to 532 ophthalmologists participated in ED coverage that year. The level of workload varied considerably depending on <I>International Classification of Diseases</I> code diagnosis. Annual workload for open wounds to the eye, on average, ranged from 2.7 to 3.1 per ophthalmologist taking ED call.</p>
<p><b>Conclusions&nbsp;</b> Strategic planning for the delivery of ED eye care needs to consider both the number and types of cases presenting to the ED and the availability of ophthalmologists to provide care that other specialists cannot. This preliminary study explores the use of a workload statistic that may help to gauge manpower needs in the future.</p>
]]></description>
<dc:creator><![CDATA[Witmer, M. T., Margo, C. E.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Medical Practice, Medical Practice, Other, Ophthalmology, Ophthalmological Disorders, Eye Injuries/ Ocular Trauma, Ophthalmology, Other, Emergency Medicine]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.269</dc:identifier>
<dc:title><![CDATA[Analysis of Ophthalmology Workforce and Delivery of Emergency Department Eye Care in Florida [Socioeconomics and Health Services]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1527</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1522</prism:startingPage>
<prism:section>Socioeconomics and Health Services</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1528?rss=1">
<title><![CDATA[Is the Risk of Incidence or Progression of Age-Related Macular Degeneration Increased After Cataract Surgery? [Editorial]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1528?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Klein, B. E. K.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Aging/ Geriatrics, Ophthalmology, Ophthalmological Disorders, Cataracts/ Lens, Macular Degeneration, Ophthalmological Procedures, Ophthalmological Procedures, Other, Patient-Physician Relationship/ Care, Patient-Physician Communication]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.258</dc:identifier>
<dc:title><![CDATA[Is the Risk of Incidence or Progression of Age-Related Macular Degeneration Increased After Cataract Surgery? [Editorial]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1529</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1528</prism:startingPage>
<prism:section>Editorial</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1530?rss=1">
<title><![CDATA[The Role of Braille in the Literacy of Blind and Visually Impaired Children [Editorial]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1530?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Massof, R. W.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Pediatric Ophthalmology, Ophthalmology, Other, Pediatrics, Pediatrics, Other, Rehabilitation Medicine]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.295</dc:identifier>
<dc:title><![CDATA[The Role of Braille in the Literacy of Blind and Visually Impaired Children [Editorial]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1531</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1530</prism:startingPage>
<prism:section>Editorial</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1532?rss=1">
<title><![CDATA[The Story of Louis Braille [Special Article]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1532?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Bullock, J. D., Galst, J. M.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmology, Other, Humanities, History of Medicine]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.286</dc:identifier>
<dc:title><![CDATA[The Story of Louis Braille [Special Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1533</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1532</prism:startingPage>
<prism:section>Special Article</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1534?rss=1">
<title><![CDATA[The Multifaceted Career of Louis Borsch [Special Article]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1534?rss=1</link>
<description><![CDATA[
<p>John Louis Borsch Jr, MD (1873-1929), was an ophthalmologist from Philadelphia who spent most of his career in France. During his lifetime he was probably best known as the inventor of the first fused bifocal lens, which was marketed very successfully as the Kryptok lens. He may be better known today for performing cataract surgery on Mary Cassatt (1844-1926), the American Impressionist artist, and on James Joyce (1882-1941), the Irish author. Little known, but remarkable, is his thesis for his second medical degree, <I>Le Traitement Chirurgical de l&rsquo;Astigmie</I> (<I>The Surgical Treatment of Astigmatism</I>).</p>
]]></description>
<dc:creator><![CDATA[Ravin, J. G.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmology, Other, Humanities, History of Medicine]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.264</dc:identifier>
<dc:title><![CDATA[The Multifaceted Career of Louis Borsch [Special Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1537</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1534</prism:startingPage>
<prism:section>Special Article</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1538?rss=1">
<title><![CDATA[{alpha}1-Adrenergic Blockers and Intraoperative Floppy-Iris Syndrome [Commentary]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1538?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Friedman, A. H.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Aging/ Geriatrics, Men's Health, Men's Health, Other, Ophthalmology, Ophthalmological Disorders, Cataracts/ Lens, Endophthalmitis, Retinal Detachment, Ophthalmological Procedures, Vitreoretinal Surgery, Ophthalmological Procedures, Other, Drug Therapy, Adverse Effects]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.280</dc:identifier>
<dc:title><![CDATA[{alpha}1-Adrenergic Blockers and Intraoperative Floppy-Iris Syndrome [Commentary]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1539</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1538</prism:startingPage>
<prism:section>Commentary</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1540?rss=1">
<title><![CDATA[Positive Aspects of the Use of Multipurpose Disinfection Solutions [Controversies]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1540?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Koffler, B. H., Karpecki, P. M.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmology, Other, Patient-Physician Relationship/ Care, Patient Education/ Health Literacy, Treatment Adherence, Drug Therapy, Adherence]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.289</dc:identifier>
<dc:title><![CDATA[Positive Aspects of the Use of Multipurpose Disinfection Solutions [Controversies]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1543</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1540</prism:startingPage>
<prism:section>Controversies</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1544?rss=1">
<title><![CDATA[Contact Lens Solutions: Part of the Problem [Controversies]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1544?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Cohen, E. J.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmology, Other, Patient-Physician Relationship/ Care, Patient Education/ Health Literacy, Treatment Adherence, Drug Therapy, Adherence]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.128</dc:identifier>
<dc:title><![CDATA[Contact Lens Solutions: Part of the Problem [Controversies]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1546</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1544</prism:startingPage>
<prism:section>Controversies</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1547?rss=1">
<title><![CDATA[Retinal Pigment Epithelial Tear in Shaken Baby Syndrome [Research Letters]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1547?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Ho, L. Y., Goldenberg, D. T., Capone, A.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Retinal/ Chorioretinal Disorders, Retinal Detachment, Ophthalmological Procedures, Vitreoretinal Surgery, Pediatrics, Child Abuse, Neonatology and Infant Care, Violence and Human Rights, Violence and Human Rights, Other]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.285</dc:identifier>
<dc:title><![CDATA[Retinal Pigment Epithelial Tear in Shaken Baby Syndrome [Research Letters]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1548</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1547</prism:startingPage>
<prism:section>Research Letters</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1548?rss=1">
<title><![CDATA[Subinternal Limiting Membrane Hemorrhage With Perimacular Fold in Leukemia [Research Letters]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1548?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Bhatnagar, A., Wilkinson, L. B., Tyagi, A. K., Willshaw, H. E.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmological Disorders, Retinal/ Chorioretinal Disorders, Ophthalmological Disorders, Other, Hematology/ Hematologic Malignancies]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.284</dc:identifier>
<dc:title><![CDATA[Subinternal Limiting Membrane Hemorrhage With Perimacular Fold in Leukemia [Research Letters]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1550</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1548</prism:startingPage>
<prism:section>Research Letters</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1550?rss=1">
<title><![CDATA[Intracisternal Irrigation of Papaverine Leading to Choroidal Infarction [Research Letters]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1550?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Reddy, S., Goldman, D. R., Kaines, A., Hubschman, J.-P., Sarraf, D.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Neurology, Cerebrovascular Disease, Ophthalmology, Ophthalmological Disorders, Retinal/ Chorioretinal Disorders, Surgery, Surgical Interventions, Neurosurgery, Drug Therapy, Adverse Effects]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.279</dc:identifier>
<dc:title><![CDATA[Intracisternal Irrigation of Papaverine Leading to Choroidal Infarction [Research Letters]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1551</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1550</prism:startingPage>
<prism:section>Research Letters</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1551?rss=1">
<title><![CDATA[Enterococcus casseliflavus Endophthalmitis Associated With a Horse Tail Injury [Research Letters]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1551?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Khurana, R. N., Leder, H. A., Nguyen, Q. D., Do, D. V.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Bacterial Infections, Ophthalmology, Ophthalmological Disorders, Endophthalmitis, Eye Injuries/ Ocular Trauma, Retinal Detachment, Ophthalmological Procedures, Vitreoretinal Surgery, Infectious Diseases]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.282</dc:identifier>
<dc:title><![CDATA[Enterococcus casseliflavus Endophthalmitis Associated With a Horse Tail Injury [Research Letters]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1552</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1551</prism:startingPage>
<prism:section>Research Letters</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1552?rss=1">
<title><![CDATA[Evolution: Theory, Not Fact [Letters]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1552?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Smiddy, W. E.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmology, Other]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.290</dc:identifier>
<dc:title><![CDATA[Evolution: Theory, Not Fact [Letters]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1553</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1552</prism:startingPage>
<prism:section>Letters</prism:section>
</item>

<item rdf:about="http://archopht.ama-assn.org/cgi/content/short/127/11/1553?rss=1">
<title><![CDATA[Evolution: Theory, Not Fact--Reply [Letters]]]></title>
<link>http://archopht.ama-assn.org/cgi/content/short/127/11/1553?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Fishman, R. S.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 12:51:48 PST</dc:date>
<dc:subject><![CDATA[Ophthalmology, Ophthalmology, Other]]></dc:subject>
<dc:identifier>info:doi/10.1001/archophthalmol.2009.291</dc:identifier>
<dc:title><![CDATA[Evolution: Theory, Not Fact--Reply [Letters]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>127</prism:volume>
<prism:endingPage>1553</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1553</prism:startingPage>
<prism:section>Letters</prism:section>
</item>

</rdf:RDF>